The regulator noted in its early 2014 retrospective that it set a high mark for the number of approved rare disease drugs this year, and that insufficient information is the reason many breakthrough status requests get bounced.
The drugmakers, who have an experimental cholesterol medication in the works, are asking consumers what they know about heart health.
The FDA's prescription drug promotion arm wrote that the professional print ad for seizure med Aptiom "misleadingly overstated its efficacy."
There needs to be a greater effort put into the issue of adherence. What can academia, providers, pharma and payers do to address this pressing need?
Once we venerated doctors. Now we question every dollar they make
"Customer service is more than just a nice-to-have. In this competitive marketplace, it can mean the difference between your brand or someone else's."